Join MeiraGTx for an investor webcast featuring key opinion leader (KOL) Professor Michel Michaelides, Consultant Ophthalmologist at Moorfields Eye Hospital, who will join company management to discuss the unmet need and current treatment landscape for children with Leber congenital amaurosis (LCA4). LCA4 is a retinal dystrophy caused by mutations in the AIPL1 gene that result in blindness from birth, with complete degeneration of the retina by the age of four. There are currently no approved treatments for LCA4.

The event will focus on reviewing data from the first-in-human interventional study evaluating the safety and efficacy of rAAV8.hRKp.AIPL1, an investigational genetic medicine designed to deliver functional copies of the AIPL1 gene to slow further degeneration and restore vision. rAAV8.hRKp.AIPL1 was awarded the Innovation Passport and granted orphan drug and rare pediatric disease designations by the FDA and orphan drug designation by the European Commission, in children with LCA4.

A live question and answer session will follow the formal presentations.